Home/Nurix Therapeutics/Gary G. Glick
GG

Gary G. Glick

Founder and Director

Nurix Therapeutics

Therapeutic Areas

Nurix Therapeutics Pipeline

DrugIndicationPhase
NX-5948Relapsed/Refractory B-cell Malignancies (CLL, NHL)Phase 1b
NX-2127Relapsed/Refractory B-cell MalignanciesPhase 1a/1b
NX-1607Advanced Solid TumorsPhase 1a
NX-0479 (GS-6791)Oncology (undisclosed)Preclinical
DeTIL-0255Solid TumorsPreclinical